This review provides a comprehensive overview of the diagnostic pathway, including (AI-enabled) electrocardiography analysis, (non-)invasive imaging modalities, biomarkers, and genetic testing, and emerging therapeutic strategies are discussed.
L. Kieviet, D. Ahmetagić, S. Muller et al.· Netherlands Heart Journal· 0 citations
BACKGROUND
Family screening is recommended in dilated cardiomyopathy (DCM), but risk stratification of relatives of probands without pathogenic or likely pathogenic variants (gene-elusive) remains uncertain.
OBJECTIVES
This study sought to define the incidence, prognosis, and predictors of disease development in firs...
A. Paldino, E. Del Mestre, I. Gandin et al.· JACC. Heart failure· 1 citation
BACKGROUND
In transthyretin amyloid cardiomyopathy, mitral regurgitation (MR) severity may be underestimated by conventional (semi-)quantitative echocardiographic criteria due to restrictive low-flow hemodynamics. We sought to define and validate disease-specific MR risk thresholds and compare their prognostic performa...
L. Hauptmann, C. Kronberger, S. Schwarting et al.· Circulation· 0 citations
BACKGROUND
Cardiomyopathy guidelines recommend routine screening of at-risk relatives with dilated cardiomyopathy (DCM). Titin-truncating variants are the most prevalent cause. However, the diagnostic yield of screening is low. Risk-based stratification could optimize screening intervals and resource allocation. This s...
S. Muller, N. Beelen, A. Paldino et al.· Circulation: Heart Failure· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.